Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000519784 | SCV000622027 | likely pathogenic | not provided | 2019-11-11 | criteria provided, single submitter | clinical testing | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 2016); Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001853701 | SCV002259952 | likely pathogenic | Loeys-Dietz syndrome 4 | 2021-04-10 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 1 of the TGFB2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TGFB2 are known to be pathogenic (PMID: 22772368, 22772371, 30739908). This variant is not present in population databases (ExAC no frequency). Disruption of this splice site has been observed in individual(s) with thoracic aortic aneurysm and/or dissection (PMID: 30739908). ClinVar contains an entry for this variant (Variation ID: 453158). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |